We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+41.81%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$368M
AUM Growth
+$22.1M
Cap. Flow
-$24.9M
Cap. Flow %
-6.76%
Top 10 Hldgs %
54.53%
Holding
62
New
16
Increased
11
Reduced
11
Closed
19

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$14M
2
ETNB
89bio
ETNB
+$13.2M
3
SAGE
Sage Therapeutics
SAGE
+$11.4M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$8.5M
5
CYTK icon
Cytokinetics
CYTK
+$8.36M

Top Sells

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$36.5M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$18.1M
3
ADAP
Adaptimmune Therapeutics
ADAP
+$11.7M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$8.43M
5
ASND icon
Ascendis Pharma A/S
ASND
+$8.21M

Sector Composition

Rank Sector Weight
1 Healthcare 73.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
26
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.53M 1.23%
802,500
+115,000
+17% +$548K
ARWR icon
27
Arrowhead Research
ARWR
$12.3B
$4.37M 1.19%
101,500
+41,500
+69% +$1.79M
CRDF icon
28
Cardiff Oncology
CRDF
$77M
$4.34M 1.18%
305,900
-101,600
-25% -$671K
OBIO icon
29
Orchestra BioMed
OBIO
$254M
$4.32M 1.17%
+392,500
New +$4.41M
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
$3.55M 0.97%
705,218
-1,047,000
-60% -$7.62M
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.78B
$3.55M 0.96%
240,744
– –
PANA.U
32
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$3.36M 0.91%
+280,000
New +$3.22M
ANNX icon
33
Annexon
ANNX
$895M
$3.33M 0.9%
+110,000
New +$2.58M
XENE icon
34
Xenon Pharmaceuticals
XENE
$6.09B
$3.32M 0.9%
300,000
-217,500
-42% -$2.56M
FULC icon
35
Fulcrum Therapeutics
FULC
$292M
$3.02M 0.82%
+381,500
New +$4.59M
CNCE
36
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$2.95M 0.8%
+300,000
New +$2.96M
VSTM icon
37
Verastem
VSTM
$562M
$2.9M 0.79%
200,000
-20,833
-9% -$345K
BCRX icon
38
BioCryst Pharmaceuticals
BCRX
$2.39B
$2.27M 0.62%
660,000
-1,240,000
-65% -$5.31M
AXSM icon
39
Axsome Therapeutics
AXSM
$10.9B
$1.6M 0.44%
22,500
-67,500
-75% -$5.26M
KRTX
40
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.04M 0.28%
13,500
-64,500
-83% -$5.5M
COGT icon
41
Cogent Biosciences
COGT
$7.22B
$959K 0.26%
+102,500
New +$1.07M
CLSD
42
DELISTED
Clearside Biomedical
CLSD
$947K 0.26%
+41,000
New +$1.06M
WVE icon
43
Wave Life Sciences
WVE
$1.18B
$913K 0.25%
107,500
– –
ADAP
44
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-1,165,000
Closed -$11.7M
ADVM
45
DELISTED
Adverum Biotechnologies
ADVM
– –
-174,650
Closed -$36.5M
AGEN
46
Agenus
AGEN
$294M
– –
-47,511
Closed -$3.67M
APLT
47
DELISTED
Applied Therapeutics
APLT
– –
-182,000
Closed -$6.58M
ARVN icon
48
Arvinas
ARVN
$570M
– –
-123,000
Closed -$4.13M
ASND icon
49
Ascendis Pharma A/S
ASND
$16.7B
– –
-55,500
Closed -$8.21M
BTAI icon
50
BioXcel Therapeutics
BTAI
$27.8M
– –
-21,281
Closed -$18.1M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q3 2020 Portfolio in Review

As of Q3 2020, Acuta Capital Partners held 62 positions worth $368M, up 6.4% from $346M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Acuta Capital Partners withdrew a net $24.9M in Q3 2020, closing 19 positions and reducing 11 holdings. Its most notable exit was Adverum Biotechnologies, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 91% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Compass Pathways worth $13.6M.

  • Acuta Capital Partners's largest Q3 2020 buy was Compass Pathways: 390,000 shares worth $13.6M.
  • Acuta Capital Partners added most to Celldex Therapeutics in Q3 2020, an estimated $6.38M increase.
  • Acuta Capital Partners's biggest Q3 2020 reduction was Iovance Biotherapeutics, cutting an estimated $8.43M.
  • Acuta Capital Partners fully exited Adverum Biotechnologies in Q3 2020, selling an estimated $36.5M.
  • Acuta Capital Partners's ten largest holdings make up 55% of its $368M portfolio in Q3 2020.
  • Acuta Capital Partners opened 16 new positions and closed 19 in Q3 2020.
  • Acuta Capital Partners's portfolio value rose 6.4% quarter-over-quarter to $368M.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.